Issue link: https://uberflip.scri.com/i/1521062
0529/24SCR019-14/R3 Abstract Presentation Calendar ASCO® 2024 9 Saturday Friday Sunday Monday Tuesday Publication Only SUNDAY, JUNE 2 ND 9:00am - 1:00pm Central Time Time Presentation Time Session Location Presentation Type Abstract Number Presentation Title 1st Author *SCRI First Author in Bold SCRI-Affiliated Coauthors Session Name 9:00am - 12:00pm Hall A Poster 1071 Real-world (RW) elacestrant use patterns and therapeutic outcomes in patients (pts) with hormone receptor- positive (HR+)/HER2-negative advanced breast cancer (aBC). Lloyd M Hamilton E Breast Cancer— Metastatic 9:00am - 12:00pm Hall A Poster 1053 Comparison of expert treatment recommendations versus community healthcare providers: Analysis from an online decision support tool for metastatic breast cancer. Mayer E Hamilton E Breast Cancer— Metastatic 9:00am - 12:00pm Hall A Poster 541 Short-term risk of recurrence in patients (pts) with HR+/HER2− early breast cancer (EBC) treated with endocrine therapy (ET) in randomized clinical trials (RCTs): A meta-analysis. Curigliano G Hamilton E Breast Cancer—Local/ Regional/Adjuvant 9:00am - 12:00pm Hall A Poster 1105 Tucatinib and trastuzumab for previously treated HER2− mutated metastatic breast cancer (SGNTUC−019): A phase 2 basket study. Okines A Hamilton E, Monk B Breast Cancer - Metastatic 9:00am - 12:00pm Hall A Poster 1051 H3B-6545 + palbociclib in patients (pts) with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (–) breast cancer (BC). Johnston S Wang J, Hamilton E Breast Cancer - Metastatic 9:00am - 12:00pm Hall A Poster 1069 Elacestrant in various combinations in patients (pts) with estrogen receptor- positive (ER+), HER2-negative (HER2- ) locally advanced or metastatic breast cancer (adv/mBC): Preliminary data from ELEVATE, a phase 1b/2, open-label, umbrella study. Rugo H O'Shaughnessy J, Hamilton E Breast Cancer— Metastatic 9:00am - 12:00pm Hall A Poster 5061 Phase 1 trial of mevrometostat (PF- 06821497), a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in castration- resistant prostate cancer (CRPC). Schweizer M Garmezy B Genitourinary Cancer— Prostate, Testicular, and Penile 9:00am - 12:00pm Hall A Poster 1064 Elacestrant in combination with abemaciclib in patients (pts) with brain metastasis from estrogen receptor-positive (ER+), HER2- negative (HER2-) breast cancer: Preliminary data from ELECTRA, an open-label, multicenter, phase 1b/2 study. Ibrahim N Hamilton E Breast Cancer— Metastatic 9:00am - 12:00pm Hall A Poster 1110 Updated safety and antitumor activity of BB-1701 from study 101 in the multiple dose level cohort of patients with locally advanced/metastatic HER2-low expressing breast cancer. Ma F Hamilton E Breast Cancer - Metastatic 9:00am - 12:00pm Hall A Poster 1023 Pooled analysis by best confirmed response to trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ metastatic breast cancer (mBC) from DESTINY-Breast-01, -02, and -03 Saura C Hamilton E Breast Cancer— Metastatic